breast neoplasms

Summary

Summary: Tumors or cancer of the human BREAST.

Top Publications

  1. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
  2. ncbi A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
  3. pmc A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
  4. pmc A pathway-based classification of human breast cancer
    Michael L Gatza
    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:6994-9. 2010
  5. ncbi Molecular portraits of human breast tumours
    C M Perou
    Department of Genetics, Stanford University School of Medicine, California 94305, USA
    Nature 406:747-52. 2000
  6. pmc Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
  7. pmc Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    T Sørlie
    Department of Genetics, The Norwegian Radium Hospital, Montebello, N 0310 Oslo, Norway
    Proc Natl Acad Sci U S A 98:10869-74. 2001
  8. pmc The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    Christina Curtis
    Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
    Nature 486:346-52. 2012
  9. ncbi The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
    Philip A Gregory
    Hanson Institute and Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Nat Cell Biol 10:593-601. 2008
  10. ncbi MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005

Detail Information

Publications263 found, 100 shown here

  1. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  2. ncbi A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
    ..A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy...
  3. pmc A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
    ..We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations...
  4. pmc A pathway-based classification of human breast cancer
    Michael L Gatza
    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:6994-9. 2010
    ..We propose that this classification scheme provides a basis for understanding the complex mechanisms of oncogenesis that give rise to these tumors and to identify rational opportunities for combination therapies...
  5. ncbi Molecular portraits of human breast tumours
    C M Perou
    Department of Genetics, Stanford University School of Medicine, California 94305, USA
    Nature 406:747-52. 2000
    ..The tumours could be classified into subtypes distinguished by pervasive differences in their gene expression patterns...
  6. pmc Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
    ..Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies...
  7. pmc Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    T Sørlie
    Department of Genetics, The Norwegian Radium Hospital, Montebello, N 0310 Oslo, Norway
    Proc Natl Acad Sci U S A 98:10869-74. 2001
    ....
  8. pmc The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    Christina Curtis
    Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
    Nature 486:346-52. 2012
    ..Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome...
  9. ncbi The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
    Philip A Gregory
    Hanson Institute and Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Nat Cell Biol 10:593-601. 2008
    ..Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression...
  10. ncbi MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005
    ..We could identify miRNAs whose expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index...
  11. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  12. pmc Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    A Goldhirsch
    International Breast Cancer Study Group, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 22:1736-47. 2011
    ..Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints...
  13. ncbi Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    D J Slamon
    Science 235:177-82. 1987
    ..These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer...
  14. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  15. pmc The clonal and mutational evolution spectrum of primary triple-negative breast cancers
    Sohrab P Shah
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada
    Nature 486:395-9. 2012
    ..Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes...
  16. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  17. pmc Supervised risk predictor of breast cancer based on intrinsic subtypes
    Joel S Parker
    Lineberger Comprehensive Cancer Center, Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 27:1160-7. 2009
    ..Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen...
  18. ncbi The consensus coding sequences of human breast and colorectal cancers
    Tobias Sjoblom
    Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Science 314:268-74. 2006
    ..These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology...
  19. ncbi Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
    Li Ma
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:682-8. 2007
    ....
  20. ncbi Involvement of chemokine receptors in breast cancer metastasis
    A Muller
    Department of Immunology, DNAX Research Institute, Palo Alto, California 94304, USA
    Nature 410:50-6. 2001
    ..Our findings indicate that chemokines and their receptors have a critical role in determining the metastatic destination of tumour cells...
  21. pmc The landscape of cancer genes and mutational processes in breast cancer
    Philip J Stephens
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
    Nature 486:400-4. 2012
    ..Among the 100 tumours, we found driver mutations in at least 40 cancer genes and 73 different combinations of mutated cancer genes. The results highlight the substantial genetic diversity underlying this common disease...
  22. pmc Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
    Brian D Lehmann
    Department of Biochemistry, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Clin Invest 121:2750-67. 2011
    ..These data may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of TNBC patients to appropriate targeted therapies...
  23. pmc An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
    Ittai Ben-Porath
    Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA
    Nat Genet 40:499-507. 2008
    ....
  24. ncbi Gene expression profiling predicts clinical outcome of breast cancer
    Laura J van 't Veer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
    Nature 415:530-6. 2002
    ..This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy...
  25. ncbi Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    Jose Baselga
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:520-9. 2012
    ..In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity...
  26. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
    ..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
  27. ncbi Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
    Jing Yang
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Cell 117:927-39. 2004
    ..These results establish a mechanistic link between Twist, EMT, and tumor metastasis...
  28. ncbi Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:557-63. 2007
    ..Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells...
  29. pmc Matrix crosslinking forces tumor progression by enhancing integrin signaling
    Kandice R Levental
    Department of Bioengineering and Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cell 139:891-906. 2009
    ..These data show how collagen crosslinking can modulate tissue fibrosis and stiffness to force focal adhesions, growth factor signaling and breast malignancy...
  30. pmc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
    ....
  31. pmc Sequence analysis of mutations and translocations across breast cancer subtypes
    Shantanu Banerji
    The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA
    Nature 486:405-9. 2012
    ..The MAGI3-AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor...
  32. ncbi The Ki-67 protein: from the known and the unknown
    T Scholzen
    Division of Molecular Immunology, Research Center Borstel, Germany
    J Cell Physiol 182:311-22. 2000
    ..There are indications, however, that Ki-67 protein expression is an absolute requirement for progression through the cell-division cycle...
  33. pmc Genes that mediate breast cancer metastasis to lung
    Andy J Minn
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 436:518-24. 2005
    ..Others contribute to aggressive growth selectively in the lung. Many encode extracellular proteins and are of previously unknown relevance to cancer metastasis...
  34. ncbi Multidrug resistance in cancer: role of ATP-dependent transporters
    Michael M Gottesman
    Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 2:48-58. 2002
    ..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
  35. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  36. pmc Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
    Aleix Prat
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Breast Cancer Res 12:R68. 2010
    ..Here, we comprehensively characterize the recently identified claudin-low tumor subtype...
  37. pmc Most random gene expression signatures are significantly associated with breast cancer outcome
    David Venet
    IRIDIA CoDE, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS Comput Biol 7:e1002240. 2011
    ..The methods we present help to overcome this problem...
  38. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  39. pmc Endogenous human microRNAs that suppress breast cancer metastasis
    Sohail F Tavazoie
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 451:147-52. 2008
    ..miR-335 and miR-126 are thus identified as metastasis suppressor microRNAs in human breast cancer...
  40. pmc American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    J Clin Oncol 28:2784-95. 2010
    ..To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers...
  41. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  42. ncbi Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    Jose Baselga
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 366:109-19. 2012
    ....
  43. ncbi The genomic landscapes of human breast and colorectal cancers
    Laura D Wood
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 318:1108-13. 2007
    ..These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy...
  44. pmc Association of reactive oxygen species levels and radioresistance in cancer stem cells
    Maximilian Diehn
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 458:780-3. 2009
    ....
  45. pmc Genome remodelling in a basal-like breast cancer metastasis and xenograft
    Li Ding
    The Genome Center at Washington University, St Louis, Missouri 63108, USA
    Nature 464:999-1005. 2010
    ..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour...
  46. ncbi PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    J Li
    Department of Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032, USA
    Science 275:1943-7. 1997
    ..These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions...
  47. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  48. pmc Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
    M P Coleman
    Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 377:127-38. 2011
    ..This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival...
  49. ncbi Triple-negative breast cancer
    William D Foulkes
    Departmentof Oncology and Human Genetics, Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC H2W 1S6, Canada
    N Engl J Med 363:1938-48. 2010
    ..This review focuses on its origin, molecular and clinical characteristics, and treatment...
  50. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  51. pmc Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group
    Mitch Dowsett
    Department of Biochemistry, Royal Marsden Hospital and Breakthrough Breast Cancer Centre, Fulham Road, London, UK
    J Natl Cancer Inst 103:1656-64. 2011
    ..These recommendations are geared toward achieving a harmonized methodology, create greater between-laboratory and between-study comparability, and allow earlier valid applications of this marker in clinical practice...
  52. pmc Whole-genome analysis informs breast cancer response to aromatase inhibition
    Matthew J Ellis
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
    Nature 486:353-60. 2012
    ..Prospective clinical trials based on these findings will require comprehensive genome sequencing...
  53. ncbi A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
    Y Miki
    Department of Medical Informatics, University of Utah Medical Center, Salt Lake City 84132
    Science 266:66-71. 1994
    ..Identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology...
  54. ncbi let-7 regulates self renewal and tumorigenicity of breast cancer cells
    Fengyan Yu
    Department of Breast Surgery, No 2 Affiliated Hospital, Sun Yat Sen University, Guangzhou 510120, People s Republic of China
    Cell 131:1109-23. 2007
    ..Therefore let-7 regulates multiple BT-IC stem cell-like properties by silencing more than one target...
  55. ncbi Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
    Jayanta Debnath
    Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Methods 30:256-68. 2003
    ....
  56. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  57. pmc Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy
    David G DeNardo
    Department of Pathology, University of California, San Francisco, USA
    Cancer Discov 1:54-67. 2011
    ....
  58. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
    ..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
  59. ncbi Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
    Xiaoxian Li
    Breast Center at Baylor College of Medicine, 1 Baylor Plaza BCM 600, TX 77030, USA
    J Natl Cancer Inst 100:672-9. 2008
    ....
  60. ncbi Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
    Mohammad H Forouzanfar
    Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
    Lancet 378:1461-84. 2011
    ..Breast and cervical cancer are important causes of mortality in women aged ≥15 years. We undertook annual age-specific assessments of breast and cervical cancer in 187 countries...
  61. pmc Genome-wide association study identifies five new breast cancer susceptibility loci
    Clare Turnbull
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 42:504-7. 2010
    ....
  62. ncbi Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
    Sohrab P Shah
    Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver V5Z 1L3, Canada
    Nature 461:809-13. 2009
    ..Taken together, our data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression...
  63. pmc Genes that mediate breast cancer metastasis to the brain
    Paula D Bos
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 459:1005-9. 2009
    ..This co-option of a brain sialyltransferase highlights the role of cell-surface glycosylation in organ-specific metastatic interactions...
  64. pmc Generation of breast cancer stem cells through epithelial-mesenchymal transition
    Anne Pierre Morel
    Centre Leon Berard, Lyon, France
    PLoS ONE 3:e2888. 2008
    ..The acquisition of these stem and tumorigenic characters is driven by EMT induction...
  65. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  66. ncbi Stromal gene expression predicts clinical outcome in breast cancer
    Greg Finak
    McGill Centre for Bioinformatics, 3775 University Street, McGill University, Quebec H3A 2B4, Canada
    Nat Med 14:518-27. 2008
    ..Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumor progression...
  67. pmc Complex landscapes of somatic rearrangement in human breast cancer genomes
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 462:1005-10. 2009
    ..The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development...
  68. ncbi Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  69. ncbi Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
    M Clarke
    Clinical Trial Service Unit, Oxford, UK
    Lancet 366:2087-106. 2005
    ..To examine this relationship, collaborative meta-analyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995...
  70. pmc Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery
    Jessica Kao
    Department of Pathology, Stanford University, Stanford, CA, USA
    PLoS ONE 4:e6146. 2009
    ..Here, we studied a collection of breast cancer cell lines to catalog molecular profiles and to assess their relation to breast cancer subtypes...
  71. ncbi Diverse somatic mutation patterns and pathway alterations in human cancers
    Zhengyan Kan
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 466:869-73. 2010
    ..Our study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets...
  72. pmc Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes
    Joseph H Taube
    Department of Molecular Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
    Proc Natl Acad Sci U S A 107:15449-54. 2010
    ..Additionally, the expression level of FOXC1, another EMT inducer, correlates strongly with poor survival of breast cancer patients...
  73. ncbi Circulating microRNAs as novel minimally invasive biomarkers for breast cancer
    Helen M Heneghan
    Department of Surgery, National University of Ireland, Galway, Ireland
    Ann Surg 251:499-505. 2010
    ..The objective of this study was to investigate the potential of circulating microRNAs as novel breast cancer biomarkers...
  74. pmc Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
    Caryn S Ross-Innes
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Nature 481:389-93. 2012
    ..By establishing transcription-factor mapping in primary tumour material, we show that there is plasticity in ER-binding capacity, with distinct combinations of cis-regulatory elements linked with the different clinical outcomes...
  75. ncbi Breast cancer statistics, 2011
    Carol DeSantis
    Epidemiologist, Surveillance Research, American Cancer Society, Atlanta, GA 30303, USA
    CA Cancer J Clin 61:409-18. 2011
    ..Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population...
  76. ncbi Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
    Elgene Lim
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    Nat Med 15:907-13. 2009
    ..Our findings suggest that an aberrant luminal progenitor population is a target for transformation in BRCA1-associated basal tumors ...
  77. ncbi Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    N Engl J Med 347:1233-41. 2002
    ..In 1976, we initiated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effective as total mastectomy for the treatment of invasive breast cancer...
  78. pmc Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 20:1319-29. 2009
    ..The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm...
  79. pmc Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression
    Douglas S Micalizzi
    Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO 80045, USA
    J Mammary Gland Biol Neoplasia 15:117-34. 2010
    ..This review focuses on the parallels between epithelial plasticity/EMT in the mammary gland and other organs during development, and on a selection of developmental EMT regulators that are misexpressed specifically during breast cancer...
  80. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  81. pmc Adjuvant trastuzumab in HER2-positive breast cancer
    Dennis Slamon
    Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    N Engl J Med 365:1273-83. 2011
    ..We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab...
  82. pmc A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis
    Scott Valastyan
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 137:1032-46. 2009
    ..Indeed, RhoA re-expression partially reverses miR-31-imposed metastasis suppression. These findings indicate that miR-31 uses multiple mechanisms to oppose metastasis...
  83. pmc Repeated observation of breast tumor subtypes in independent gene expression data sets
    Therese Sorlie
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 100:8418-23. 2003
    ..Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities...
  84. pmc Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells
    Yohei Shimono
    Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, CA 94304, USA
    Cell 138:592-603. 2009
    ..The coordinated downregulation of three microRNA clusters and the similar functional regulation of clonal expansion by miR-200c provide a molecular link that connects BCSCs with normal stem cells...
  85. ncbi American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
  86. ncbi Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells
    Lisa B Frankel
    Biotech Research and Innovation Centre, Bioinformatics Centre, University of Copenhagen, DK 2200 N Copenhagen, Denmark
    J Biol Chem 283:1026-33. 2008
    ..We furthermore found that the tumor suppressor protein Programmed Cell Death 4 (PDCD4) is regulated by miR-21 and demonstrated that PDCD4 is a functionally important target for miR-21 in breast cancer cells...
  87. pmc MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
    Tyler E Miller
    Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 283:29897-903. 2008
    ..This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker...
  88. pmc microRNAs exhibit high frequency genomic alterations in human cancer
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 103:9136-41. 2006
    ..These findings support the notion that copy number alterations of miRNAs and their regulatory genes are highly prevalent in cancer and may account partly for the frequent miRNA gene deregulation reported in several tumor types...
  89. ncbi miR-21-mediated tumor growth
    M L Si
    Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
    Oncogene 26:2799-803. 2007
    ..Together, these results suggest that miR-21 functions as an oncogene and modulates tumorigenesis through regulation of genes such as bcl-2 and thus, it may serve as a novel therapeutic target...
  90. pmc Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Cancer Res 69:1302-13. 2009
    ....
  91. ncbi A multigenic program mediating breast cancer metastasis to bone
    Yibin Kang
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Cell 3:537-49. 2003
    ....
  92. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA and the College of American Pathologists, Northfield, IL, USA
    Arch Pathol Lab Med 131:18-43. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2(HER2) testing in invasive breast cancer and its utility as a predictive marker...
  93. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
    ....
  94. ncbi Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Charles L Vogel
    University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
    J Clin Oncol 20:719-26. 2002
    ..To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer...
  95. ncbi Metastatic behavior of breast cancer subtypes
    Hagen Kennecke
    Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:3271-7. 2010
    ..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
  96. ncbi Induction of autophagy and inhibition of tumorigenesis by beclin 1
    X H Liang
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Nature 402:672-6. 1999
    ..These findings suggest that decreased expression of autophagy proteins may contribute to the development or progression of breast and other human malignancies...
  97. pmc Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
    Jason I Herschkowitz
    Lineberger Comprehensive Cancer Center
    Genome Biol 8:R76. 2007
    ..To address this need, we characterized mammary tumor gene expression profiles from 13 different murine models using DNA microarrays and compared the resulting data to those from human breast tumors...
  98. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  99. ncbi The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation
    Tiffany M Phillips
    Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095 1714, USA
    J Natl Cancer Inst 98:1777-85. 2006
    ..Cancer-initiating cells can now be prospectively isolated from breast cancer cell lines and tumor samples and propagated as mammospheres in vitro under serum-free conditions...
  100. pmc A systems biology approach for pathway level analysis
    Sorin Draghici
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48202, USA
    Genome Res 17:1537-45. 2007
    ..This analysis method has been implemented as a Web-based tool, Pathway-Express, freely available as part of the Onto-Tools (http://vortex.cs.wayne.edu)...
  101. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases...

Research Grants78

  1. Roles of NF-kB/Rel in the pathogenesis of breast cancer
    Gail E Sonenshein; Fiscal Year: 2012
    ..Thus, pre-clinical testing of green tea components on breast cancer cells that are resistant to antibody therapy will be performed, and if successful, this approach can readily be translated to the clinic. ..
  2. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben-Jonathan; Fiscal Year: 2013
    ..The long term goal is to establish FDA-approved, long acting dopamine agonists as suppressor or PRL secretion, resulting in increased efficacy of chemotherapeutic agents in breast cancer patients. ..
  3. Developing miRNA diagnostic methods and identifying tumor regulatory networks
    Thomas Tuschl; Fiscal Year: 2010
    ....
  4. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline F Bromberg; Fiscal Year: 2010
    ....
  5. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2011
    ..Nanotechnology has made major contributions to BrCa therapy. We propose an innovative nanotechnology-based approach for BrCa prevention and treatment that could significantly impact patient care. ..
  6. PET TUMOR AND PROLIFERATION IMAGING VIA CATIONIC AMINO ACID TRANSPORT
    JONATHAN EDWARD MCCONATHY; Fiscal Year: 2013
    ..Completion of the research and training plan would position me to become an independent investigator at the conclusion of the award period. ..
  7. Exercise, Breast Cancer Prevention, and Mechanisms
    Henry J Thompson; Fiscal Year: 2013
    ..The data obtained has the potential to facilitate the translation of pre-clinical and clinical research to public health guidelines for PA directed to cancer prevention and control. ..
  8. The Role of Long Non-coding RNAs in EMT and Cancer Stem Cells
    Jason I Herschkowitz; Fiscal Year: 2013
    ....
  9. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2013
    ..This provides the potential for rapid screening to establish individualized patient-specific molecular targets and forms the basis for designing personalized prevention and treatments. ..
  10. Characterizing Mitochondrial DNA Susceptibility to Breast, Colorectal, and Prosta
    Iona Cheng; Fiscal Year: 2012
    ..In addition, we will evaluate heterogeneity of effects by disease sub-groups, environmental factors and known genetic risk factors. ..
  11. PROGESTIN AND GROWTH FACTOR CROSS-TALK IN BREAST CANCER
    CAROL ANN LANGE; Fiscal Year: 2010
    ..This work will aid our understanding of steroid hormone action, and help to identify and implicate new therapeutic targets for breast cancer prevention and treatment. ..
  12. Pososome Regulated Monocyte/Macrophage Tissue Infiltration
    Dianne Cox; Fiscal Year: 2013
    ....
  13. Alcohol and Breast Cancer
    Jia Luo; Fiscal Year: 2012
    ..Understanding the interactions among alcohol, ErbB2 and MUC1 will also provide an important insight into the pathogenesis of some human diseases related to alcohol abuse as well as alcohol's teratogenic effect during development. ..
  14. Role of an RNA-Binding Protein in Mammary Carcinogenesis
    Jeffrey Ross; Fiscal Year: 2009
    ..By investigating the oncogenic properties of the CRD-BP, the RNAs it affects in vivo, and its interactions with tumor-inducing genetic and environmental factors, we hope to uncover novel tumorigenesis pathways. ..
  15. Mechanisms of Action and Signaling by Steroid Hormone Antagonists
    Douglas V Faller; Fiscal Year: 2013
    ....
  16. Crosstalk between estrogen receptor and NFkB in target gene regulation
    Jonna Frasor; Fiscal Year: 2013
    ....
  17. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2010
    ..This study will also help us design future clinical trials based on these molecular predictions. ..
  18. Protein-DNA Drug Carriers for Tumor Targeting
    Lali K Medina-Kauwe; Fiscal Year: 2012
    ..As HER2+ breast cancer does not respond well to conventional therapies, this alternative therapy could provide a significant contribution to breast cancer treatment, and could be modified to target therapy to other types of cancer. ..
  19. Role of Splicing Factors in Breast Cancer
    OLGA ANCZUKOW-CAMARDA; Fiscal Year: 2013
    ..This plan will establish the basis for my independent research program, in which I plan to contribute to the development of new cancer therapies based on modulating the expression and activity of splicing factors or their targets. ..
  20. Systems microscopy analysis of tumor cell motility in microenvironment context
    Bojana Gligorijevic; Fiscal Year: 2013
    ..Results of this study will lead to better understanding of the interplay among microenvironment components during tumor progression and the results will be used to improve diagnosis and treatment of early metastasis. ..
  21. Mechanisms of Src activation and its role in latent bone metastasis of breast and
    Xiang H F Zhang; Fiscal Year: 2010
    ..Because of the availability of FDA-approved Src inhibitors, this study will carry significant clinical implications and may suggest novel therapeutic strategies that can be immediately subject to clinical trials. ..
  22. Near-Infrared Fluorescent Choline Kinase Inhibitors for Cancer Imaging and Therap
    SEAN ARLAUCKAS; Fiscal Year: 2013
    ..Higher-dose regimens will then be formulated, and tumor growth delay and animal survival measurements compared to MN58b. ..
  23. Regulation of miRNA in breast cancer
    Carolyn M Klinge; Fiscal Year: 2013
    ....
  24. Exploiting synthetic-lethal interactions to target triple-negative breast cancers
    Dai Horiuchi; Fiscal Year: 2013
    ..If successful, the proposed research will not only expand our knowledge on MYC biology but will also provide novel therapeutic concepts to be tested again patients with TN tumors. ..
  25. Genomewide Determinants Of Prognosis And Treatment Of Early-Onset Breast Cancer
    Habibul Ahsan; Fiscal Year: 2010
    ..We will characterize the biological effects of the genetic factors we identify using various techniques comprehensively characterize breast tumors based on molecular features related to tumor DNA and RNA. ..
  26. Ron Receptor Tyrosine Kinase Signaling in Breast Cancer
    Susan E Waltz; Fiscal Year: 2013
    ..The focus of this proposal is to define the role of a novel protein, termed Ron, and Ron- dependent signaling pathways as potential new therapeutic targets to combat this disease. ..
  27. Detection of Tumor DNA in Plasma from Carolina Breast Cancer Study Patients
    KATHLEEN CONWAY DORSEY; Fiscal Year: 2013
    ..We expect the results of this work will facilitate development of improved biomarkers for cancer diagnosis, treatment effects, and prognosis and disease recurrence in breast cancer. ..
  28. Role of Phospho-Progesterone Receptors (PR) in Hormone Refractory Breast Cancer
    CAROL ANN LANGE; Fiscal Year: 2013
    ..Our studies on phospho- PR signaling will provide valuable insight into the coordinated regulation of PR and ER function by pathways that can be easily targeted for therapeutic intervention. ..
  29. Technology to improve the assessment of tissue-associated protein biomarkers
    JEFFREY THOMAS MASON; Fiscal Year: 2013
    ..It will also facilitate the detection and prognostic assessment of breast tumors at earlier stages where clinical options are greatest and where treatment outcomes are most likely to be favorable. ..
  30. Non-genomic actions of estrogen in breast cancer
    Ellis R Levin; Fiscal Year: 2013
    ..The clinical significance is to understand new actions of estrogen and tamoxifen that are important to breast cancer biology, possibly targeting membrane or mitochondrial ER for preventing or treating breast cancer. ..
  31. Regulation of miRNA expression in breast cancer cells
    CAROLYN KLINGE; Fiscal Year: 2009
    ..It is our long term hope that miRNAs may provide novel biomarkers and new insights into the mechanisms by which breast tumors gain TAM/antiestrogen-resistance and become invasive and metastatic. ..
  32. Prevalence of CD24 epigenetic silencing in breast tumors and ERalpha status
    Benny Abraham Kaipparettu; Fiscal Year: 2012
    ..Results from this pilot study will provide important data to plan future larger studies to better understand the role of this silencing in therapeutic resistance and clinical outcome. ..
  33. FUNCTION OF THE CALCIUM SENSING RECEPTOR IN THE BREAST
    John J Wysolmerski; Fiscal Year: 2013
    ..Aim 3 will examine if stimulation of PTHrP production by the CaR contributes to the development of osteolytic bone metastases in vivo. ..
  34. Imaging Mitochondrial Redox States In Vivo by Hyperpolarized MR
    Lin Z Li; Fiscal Year: 2013
    ..This project may also establish the mitochondrial redox state as a biomarker for cancer diagnosis and treatment response, and a target for therapy. ..
  35. The role of tristetraprolin in control of breast cancer progression
    Jianguo Liu; Fiscal Year: 2013
    ....
  36. INTEGRIN FUNCTION AND SIGNALING IN CARCINOMA PROGRESSION
    Arthur M Mercurio; Fiscal Year: 2012
    ..The involvement of SOX9 in basal-like tumors and its relationship to the beta4 signature will also be assessed. ..
  37. A novel biotherapeutic for triple-negative breast cancer.
    Randolph C Elble; Fiscal Year: 2010
    ..We determine how it causes tumor cell death. We determine the structural feature responsible and its target on the tumor cell. ..
  38. Mechanisms of Breast Tumor Cell Growth, Motility, and Antiestrogen Response
    Amy H Bouton; Fiscal Year: 2013
    ..abstract_text> ..
  39. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2012
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
  40. Immunotherapy of breast cancer with T cells sensitized by cancer stem-like cells
    Li Xin Wang; Fiscal Year: 2013
    ..It is anticipated that these studies would provide leads toward development of T cell immunotherapy of breast cancer. ..
  41. Mitochondrial Genetic Susceptibility to Breast and Prostate Cancers
    Iona Cheng; Fiscal Year: 2013
    ..The ultimate application of these findings may improve the prevention, diagnosis and treatment of cancers of the breast and prostate. ..
  42. Asthma is a Prognostic Indicator for Pulmonary Metastasis of Breast Cancer
    JAMES JOSEPH LEE; Fiscal Year: 2010
    ..g., enhanced treatment protocols) aggressively targeting the asthma of breast cancer patients with the expectation of increased survival rates among this large subset of breast cancer patients. ..
  43. Targeting Cathepsin L: A Novel Strategy to Impede Prostate and Breast Cancer Meta
    Dietmar W Siemann; Fiscal Year: 2013
    ....
  44. Identifying a network of microRNAs and genes that regulate breast tumor metastasi
    Huiping Liu; Fiscal Year: 2012
    ..This application proposes a 1-year mentored phase (100% effort) and a 3-year independent phase (80% effort) to complete the research and training goals. ..
  45. Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches
    HEIKE ELIZABETH DALDRUP-LINK; Fiscal Year: 2012
    ..abstract_text> ..
  46. TRANSCRIPTIONAL REGULATION OF BREAST CANCER METASTASIS
    Zena Werb; Fiscal Year: 2012
    ..We postulate that GATA-3 maintains the differentiation of breast neoplasms, and its loss plays a causal role in malignant progression: During neoplastic progression, GATA-3 maintains ..
  47. Role of CITED2 in Breast Cancer Bone Metastasis
    Scott L Kominsky; Fiscal Year: 2013
    ..If successful, these studies will identify a novel mediator of bone metastasis and a new avenue for its prevention and treatment. ..
  48. Role of PALB2 in the DNA damage response and breast cancer suppression
    Bing Xia; Fiscal Year: 2013
    ..g. double strand breaks, interstrand crosslinks, etc. Finally, in the longer term the mouse models generated and characterized here may prove useful for pre-clinical testing of cancer drugs. ..
  49. Regulation of Breast Cancer Growth by MLK-3
    AJAY NMN RANA; Fiscal Year: 2013
    ..Further, our results will point to the possibility of utilizing MLK inhibitor(s) as a novel therapeutic intervention for breast cancer therapy. ..
  50. The optimization of compounds that selectively inhibit protein synthesis for the
    CATHY A SWINDLEHURST; Fiscal Year: 2013
    ....
  51. Cell Death Regulation in Lumen Formation and Oncogenesis
    JOAN SIEFERT BRUGGE; Fiscal Year: 2012
    ....
  52. Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ER
    Christopher Benz; Fiscal Year: 2013
    ....
  53. Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
    Celina G Kleer; Fiscal Year: 2012
    ..These studies may form the basis of intervention and therapy in breast cancer, potentially preventing premalignant lesions from becoming malignant and metastasizing. ..
  54. Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality
    Amy M Fulton; Fiscal Year: 2012
    ..We will examine these relationships further in order to identify how to restore the balance between protective and anti-protective EP receptor function to reduce mortality from metastatic breast cancer. ..
  55. Breast cancer prevention with Nexrutine
    SUSAN PATRICIA LANZA-JACOBYY; Fiscal Year: 2012
    ..We also plan to determine mechanisms by which Nexrutine is inducing autophagy by interrogating the role of ERK and Akt/mTOR signaling and reactive oxygen species (ROS) in mediating these effects. ..
  56. Mechanisms of ATF3-induced mammary tumorigenesis
    Michael C MacLeod; Fiscal Year: 2011
    ..abstract_text> ..
  57. MCJ function in mouse mammary tumor properties
    Mercedes Rincon; Fiscal Year: 2009
    ..Considering the strong need for chemotherapy response biomarkers in cancer, this project is highly relevant for human health. ..
  58. Environmental Epigenetics and Stem/Progenitor Cell Injury
    Tim H M Huang; Fiscal Year: 2010
    ..These loci are future biomarkers for early breast cancer detection and are putative biosensors to environmental estrogens. ..
  59. Second line breast cancer therapy through a novel Phytoantiestrogen
    SYREETA LATATIA TILGHMAN; Fiscal Year: 2013
    ....
  60. BP1 and Nuclear Hormone Signaling in Breast Cancer
    JOSEPH PINZONE; Fiscal Year: 2009
    ..Schwartz, Fontana, and Ascensao will provide overarching scientific and career guidance and independent ongoing peer review. Finally, Dr. Schaffner will mentor my training in the responsible conduct of research. ..
  61. Characterization of a GPCR-blocking antibody for the treatment of breast cancer.
    GARRET GUENTHER; Fiscal Year: 2011
    ..Completion of the proposed project will determine if this new drug is likely to be effective in treating breast tumors. ..
  62. Epidemiology of Breast Cancer Subtypes in African American Women: a Consortium
    Julie R Palmer; Fiscal Year: 2013
    ..By pooling our data, specimens, and importantly, expertise to investigate these synergist hypotheses, we will elucidate much of the etiology of aggressive, early onset breast cancers in AA women. ..
  63. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2003
    ..This information can also provide a scientific basis to prioritize herbs for clinical trials evaluation for their ability to prevent and treat breast cancer. ..
  64. Molecular Epidemiology of Secondary Lung Cancer
    Peter Shields; Fiscal Year: 2007
    ..RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page .................................................................................................................................................. 1 Description, ..
  65. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2005
    ..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
  66. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2006
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  67. HETEROGENEITY OF ESTROGEN RECEPTOR STRUCTURE AND ACTION
    Beth Schachter; Fiscal Year: 1993
    ....
  68. BREAST CANCER METASTASES TO BONE--ROLE OF PTHRP & TGFB
    Theresa Guise; Fiscal Year: 2000
    ..Combinations of bisphosphonates with factor-specific therapy will be studied for synergistic effects. ..
  69. ORGANOCHLORINE COMPOUNDS AND RISK OF BREAST CANCER
    Tongzhang Zheng; Fiscal Year: 1993
    ..Statistical analyses will be performed using standard multivariable techniques to address the study hypotheses and to control for confounding...
  70. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2009
    ....
  71. Molecular Epidemiology of Smoking & Breast Cancer
    KATHLEEN CONWAY DORSEY; Fiscal Year: 2005
    ..If breast cancer can be attributed, in part, to cigarette smoking, then smoking prevention or cessation should reduce exposure and thus decrease the incidence of breast cancer. ..
  72. Interactions Between Dietary Soy Components & Tamoxifen
    Jin Rong Zhou; Fiscal Year: 2003
    ....
  73. Dietary lignan effects on hormone, growth, and signaling factors in breast tumors
    Susan McCann; Fiscal Year: 2009
    ..The results of this study may provide us with important information that can be useful in understanding the effect of diet on development of different breast cancer sub-types. ..
  74. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  75. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2005
    ..abstract_text> ..
  76. ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPY
    Giuseppe Pizzorno; Fiscal Year: 2004
    ..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
  77. Breast CT scanner for earlier cancer detection
    John Boone; Fiscal Year: 2002
    ..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
  78. Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer
    Raghuraman Kannan; Fiscal Year: 2009
    ..This has the potential to improve the early detection and diagnosis of breast cancer. ..